MediWound (NASDAQ:MDWD) COO Shmuel Hess Sells 3,958 Shares of Stock

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 3,958 shares of the stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shmuel Hess also recently made the following trade(s):

• On Wednesday, August 26th, Shmuel Hess sold 1,865 shares of MediWound stock. The shares were sold at an average price of $13.00, for a total transaction of $24,245.00.

MediWound Stock Down 4.4%

Shares of MDWD stock opened at $12.66 on Friday. The firm has a market cap of $162.68 million, a price-to-earnings ratio of -7.03 and a beta of 0.15. The company’s 50 day moving average is $14.16 and its 200 day moving average is $15.64. MediWound Ltd. has a 52-week low of $12.52 and a 52-week high of $20.30.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The business had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. Analysts anticipate that MediWound Ltd. will post -2.31 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several hedge funds have recently made changes to their positions in MDWD. Rhumbline Advisers lifted its position in MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 481 shares during the period. Russell Investments Group Ltd. grew its stake in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of MediWound in the fourth quarter worth about $26,000. 46.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on MDWD shares. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Wall Street Zen lowered MediWound from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Oppenheimer restated an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, MediWound has an average rating of “Hold” and an average target price of $33.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.